Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) FCF Margin (2022 - 2025)

Historic FCF Margin for Taysha Gene Therapies (TSHA) over the last 4 years, with Q2 2025 value amounting to 1035.75%.

  • Taysha Gene Therapies' FCF Margin rose 9254900.0% to 1035.75% in Q2 2025 from the same period last year, while for Sep 2025 it was 1349.64%, marking a year-over-year decrease of 5485600.0%. This contributed to the annual value of 979.23% for FY2024, which is 4816100.0% down from last year.
  • As of Q2 2025, Taysha Gene Therapies' FCF Margin stood at 1035.75%, which was up 9254900.0% from 957.56% recorded in Q1 2025.
  • Taysha Gene Therapies' FCF Margin's 5-year high stood at 7346.13% during Q1 2022, with a 5-year trough of 1961.24% in Q2 2024.
  • Its 4-year average for FCF Margin is 431.01%, with a median of 683.05% in 2023.
  • Per our database at Business Quant, Taysha Gene Therapies' FCF Margin plummeted by -78579200bps in 2023 and then skyrocketed by 9254900bps in 2025.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' FCF Margin stood at 950.42% in 2022, then soared by 53bps to 447.67% in 2023, then tumbled by -102bps to 905.34% in 2024, then decreased by -14bps to 1035.75% in 2025.
  • Its FCF Margin was 1035.75% in Q2 2025, compared to 957.56% in Q1 2025 and 905.34% in Q4 2024.